Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm

Risk Conference Proceedings › Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm
Whitepaper

Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm

By Glenn A. Van Buskirk, Satish Asotra, Christopher Balducci, Prabir Basu, Gerald DiDonato, Angelica Dorantes, W. Mark Eickhoff, Tapash Ghosh, Mario A. González, Theresa Henry, Matthew Howard, Jason Kamm, Steven Laurenz, Ryan MacKenzie, Richard Mannion, Patrick K. Noonan, Terrance Ocheltree, Umesh Pai, Richard P. Poska, Michael L. Putnam, Ramani R. Raghavan, Colleen Ruegger, Eric Sánchez, Vinod P. Shah, Zezhi Jesse Shao, Russell Somma, Vijay Tammara, Avinash G. Thombre, Bruce Thompson, Robert J. Timko, Satyam Upadrashta & Sivakumar Vaithiyalingam · September 14, 2026
Abstract

In this whitepaper, the Manufacturing Technical Committee of the Product Quality Research Institute provides information on the common, best practices in use today in the development of high-quality chemistry, manufacturing and controls documentation. Important topics reviewed include International Conference on Harmonization, in vitro–in vivo correlation considerations, quality-by-design approaches, process analytical technologies and current scale-up, and process control and validation practices. It is the hope and intent that this whitepaper will engender expanded dialog on this important subject by the pharmaceutical industry and its regulatory bodies.

Publication Details
Type Whitepaper
Volume 15
Issue No. pages 665-693
Published Sep 14, 2026
Open Access 👁 View Paper ↓ Download Paper
← Back to Proceedings